Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer
Study Details
Study Description
Brief Summary
This is a prospective, randomized (1:1) controlled trial that will be carried out on 50 patients who are candidate to evaluate the effect of montelukast on doxorubicin induced cardiotoxicity after 4 cycles of AC. Patients will be randomly allocated into two equal groups (25 patients each); group (A) for controlled (placebo), and group (B) for montelukast. Blood samples will be collected from the study subjects and analyzed for serum levels of the NF-KB and pro-BNP. Assessment of the biomarkers will be done at two time points: at baseline and after treatment with montelukast.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
The primary objective of this study is to evaluate the effect of montelukast on doxorubicin induced cardiotoxicity in breast cancer patients through assessing serum NT-proBNP and NF-KB. The secondary objective is to evaluate the safety and side effects of montelukast on doxorubicin induced cardiotoxicity in breast cancer patients.
Methodology and study design:
-
Ethical committee approval will be obtained from Ethics committee of Faculty of Pharmacy, Damanhour University.
-
About 50 patients who are candidate to the study will be recruited from Damanhour Cancer Institute.
-
All participants will provide an informed consent.
-
Demographic data; age (year), sex (female/male), weight (kg), height (cm), BMI (kg/m2) will be collected.
-
About 5 ml of venous blood will be withdrawn by antecubital venipuncture from each participant at baseline and after receiving montelukast 10 mg once daily at bed time for 4 cycles of AC. At each time point blood samples will be collected into plain test tubes and centrifuged at 4500×g for 10 min and serum will be frozen at - 80 ◦C until analysis of the biomarkers using ELISA kits.
-
Montelukast tablets will be provided on monthly intervals and the participants' adherence will be assessed through the medications refilling rate. Participants will also be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence and report any drug related adverse effects.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Placebo Comparator: Group A group (A) will recieved placebo tablet. |
Other: Placebo
Patients will receive placebo tablets for 4 cycles of AC.
Other Names:
|
Active Comparator: Group B Patients will receive motelukast 10 mg for 4 cycles of AC. |
Drug: Montelukast
Patients will receive motelukast 10 mg for 4 cycles of AC.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- NF-KB [6 months]
serum concentration of the NF-KB (ng/dl)
- pro-BNP [6 months]
serum concentration of the pro-BNP (ng/dl)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult patients (age≥18 and≤ 70years old) with biopsy-confirmed diagnosis of breast cancer according to the American Joint Committee on Cancer (TNM staging system).
-
Patients with performance status (<2) according to Eastern Cooperative Oncology Group (ECOG).
-
Patients with adequate hematologic parameters (absolute neutrophil count≥1.5× 109/L, platelet count≥100× 109/L, hemoglobin level≥10 g/dl), adequate liver function (serum bilirubin<1.5 mg/dl), and adequate renal function (serum creatinine<1.5 mg/dl, creatinine clearance (CrCl)>45 ml/min).
Exclusion Criteria:
-
Patients who refuse to sign the written consent.
-
If blood cell counts are too low.
-
Severe liver problem.
-
Recent heart attack or have severe heart problems.
-
Previous treatment with Doxorubicin or certain other anticancer medications.
-
Allergy to certain other anti-cancer medicines, doxorubicin hydrochloride, Cis-platin, vincristine, paclitaxel, docetaxel, foscarnet, etc.
in the last 6 months.
-
Women with evidence of metastasis at the initial assessment.
-
Presence of clinical evidence for severe cardiac illness (angina pectoris, uncontrolled hypertension, arrhythmias, and left ventricular ejection fraction<50%).
-
Pregnant and breast-feeding women.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Damanhour Oncology Center | Damanhūr | Elbehairah | Egypt | 31527 |
Sponsors and Collaborators
- Damanhour University
Investigators
- Study Director: Noha A. El bassiouny, Lecturer, Damanhour University
Study Documents (Full-Text)
None provided.More Information
Publications
- Elnoury HA, Elgendy SA, Baloza SH, Ghamry HI, Soliman M, Abdel-Aziz EA. Synergistic impacts of Montelukast and Klotho against doxorubicin-induced cardiac toxicity in Rats. Toxicol Res (Camb). 2022 Jun 20;11(4):592-604. doi: 10.1093/toxres/tfac023. eCollection 2022 Aug.
- Said MM, Bosland MC. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate. Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):197-205. doi: 10.1007/s00210-016-1325-4. Epub 2016 Dec 1.
- Montelukast in Breast cancer